Ergomed logo

ERGO - Ergomed News Story

615p 30.0  5.1%

Last Trade - 4:29pm

Sector
Healthcare
Size
Small Cap
Market Cap £283.2m
Enterprise Value £274.4m
Revenue £68.3m
Position in Universe 671st / 1819

Ergomed plc - Result of AGM

Wed 10th June, 2020 10:53am
RNS Number : 5431P
Ergomed plc
10 June 2020
 

 

 

PRESS RELEASE

 

Results of 2020 Annual General Meeting

 

Guildford, UK - 10 June 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting ('AGM') held earlier today.  All resolutions were duly passed.

 

Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:

 

Resolution number

Votes for

Votes against

Abstentions

1

40,377,405

755,572

26,824

2

41,074,246

84,305

1,250

3

41,121,902

37,899

Nil

4

41,148,702

9,849

1,250

5

34,189,991

6,044,148

925,662

6

40,732,147

426,404

1,250

7

36,281,712

4,878,089

Nil

8

33,049,246

8,109,305

1,250

9

33,049,891

8,109,910

Nil

 

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman)


Richard Barfield (Chief Financial Officer)

 




 

Numis Securities Limited

 

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)


James Black (Broker)

 




 

Consilium Strategic Communications - for UK enquiries

 

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser




 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGFIFEARFIILII
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.